Wednesday, March 14, 2012
Reuters
Regeneron Pharmaceuticals Inc said surveys suggest its Eylea treatment for macular degeneration is capturing 60 percent of its sales from patients that have abandoned Roche Holding AG's Lucentis and Avastin medicines.